Discounted Cash Flow
Neogenomics Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $244.1m | $-5.7m | $13.9m | -2.3% | — |
| 2017 | $258.6m (6.0%) | $-846.0k (85.2%) | $4.3m (-68.8%) | -0.3% (86.0%) | — |
| 2018 | $276.7m (7.0%) | $2.6m (412.1%) | $30.5m (601.1%) | 1.0% (391.6%) | — |
| 2019 | $408.8m (47.7%) | $8.0m (203.3%) | $3.3m (-89.0%) | 2.0% (105.3%) | — |
| 2020 | $444.4m (8.7%) | $4.2m (-47.9%) | $-27.6m (-927.4%) | 0.9% (-52.1%) | — |
| 2021 | $484.3m (9.0%) | $-8.3m (-300.1%) | $-8.3m (69.8%) | -1.7% (-283.6%) | — |
| 2022 | $509.7m (5.2%) | $-144.2m (-1628.2%) | $-96.9m (-1060.7%) | -28.3% (-1542.1%) | — |
| 2023 | $591.6m (16.1%) | $-88.0m (39.0%) | $-30.7m (68.3%) | -14.9% (47.5%) | — |
| 2024 | $660.6m (11.6%) | $-78.7m (10.5%) | $-34.0m (-10.9%) | -11.9% (19.8%) | — |
| 2025 | $727.3m (10.1%) | $-108.0m (-37.2%) | $-21.8m (36.0%) | -14.9% (-24.6%) | — |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.